China Biologic has received sales orders on all the products that have been registered under the Central Drugs Standard Control Organization, the drug control administration in India. Those registered products include human hepatitis B Immunoglobulin 100IU/200IU and human immunoglobulin (ph4) for intravenal injection 2.5gm/5gm.
The first shipment order of $0.25 million has been delivered, and the company expects to complete the rest of the sales order before January 31, 2009.
In an effort to expand into the international market, the company has established its own international sales department focused on applying for product registration and obtaining permission to sell China Biologic’s products under its own brand in other countries.
Chao Ming Zhao, CEO of China Biologic Products, said: “We are pleased to announce our entry into the international market where the quality of our products has been recognized. The international market is an even more attractive market than the People’s Republic of China for our long term growth strategy as our products can command higher selling prices, thereby increasing our profit margins.”